Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvette Kasamon

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Transplantation|July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorderLode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Haematologica|May 7, 2016
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphomaConnie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2017
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived MalignancyRobbie G Majzner, Huzefa Mogri, Ravi Varadhan, et al.
Leukemia & Lymphoma|July 16, 2011
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasDouglas E Gladstone, Javier Bolaños-Meade, Carol Ann Huff, et al.
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
JAMA|June 21, 2021
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 StatementAaron M Orkin, Peter J Gill, Davina Ghersi, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Transplantation|July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorderLode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Haematologica|May 7, 2016
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphomaConnie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2017
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived MalignancyRobbie G Majzner, Huzefa Mogri, Ravi Varadhan, et al.
Leukemia & Lymphoma|July 16, 2011
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasDouglas E Gladstone, Javier Bolaños-Meade, Carol Ann Huff, et al.
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
JAMA|June 21, 2021
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 StatementAaron M Orkin, Peter J Gill, Davina Ghersi, et al.
Pageof 2